Angiotensin II receptor blocker attenuates stress pressor response in young adult African Americans. 2019

Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
Department of Population Health Sciences, Georgia Prevention Institute, Augusta University, Augusta, Georgia.

African Americans (AAs) are susceptible to hypertension (HTN) and its associated organ damage leading to adverse cardiovascular (CV) outcomes. Psychological stress is proposed to contribute to the development of HTN; however, the potential role of the renin-angiotensin system (RAS) in stress-related HTN in AAs is largely unknown. In this study, we tested the hypothesis that activation of RAS is a potential contributing factor for altered CV responses to stress, and suppression of angiotensin II (Ang II) activity will improve hemodynamic responses to a prolonged mental stressor in healthy young AAs. Utilizing a double-blind, randomized, crossover study design, 132 normotensive AAs (25 ± 7 years) were treated with either a placebo (PLC) or 150 mg/d irbesartan (an Ang II type 1 receptor blocker; ARB) for 1 week. On the final day of each treatment, hemodynamic measures and urinary sodium excretion (UNaV) were collected before, during and after a 45 minute-mental stress. The magnitude of stress-induced increase in blood pressure with ARB was blunted and delayed compared to PLC. Systolic blood pressure at the end of recovery on ARB was significantly lower compared to either PLC (110 ± 13 vs 117 ± 12 mm Hg respectively; P < 0.001) or the prestress level on ARB (P = 0.02). ARB treatment reduced overall vasoconstriction and improved poststress UNaV. ARB attenuated blood pressure responses to mental stress and improved the poststress BP recovery process which were partly linked to reduced overall vasoconstriction and improved stress-induced UNaV in young adult AAs prior to the development of disease conditions. These results suggest that treatment approaches that inhibit RAS action could have significant relevance to potentially lower susceptibility to stress responses and eventually the premature development of HTN in AAs.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D001741 Black or African American A person having origins in any of the black racial groups of Africa (https://www.federalregister.gov/documents/1997/10/30/97-28653/revisions-to-the-standards-for-the classification-of-federal-data-on-race-and-ethnicity). In the United States it is used for classification of federal government data on race and ethnicity. Race and ethnicity terms are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. African American,African Americans,African-American,Afro-American,Afro-Americans,Black Americans,Blacks,Negroes,African-Americans,Negro,Afro American,Afro Americans,American, African,American, Black,Black American
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
August 2019, Journal of clinical hypertension (Greenwich, Conn.),
Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
October 2000, Journal of cardiovascular pharmacology,
Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
January 2021, Physiological reports,
Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
January 2018, Ethnicity & disease,
Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
June 2011, Cardiovascular toxicology,
Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
May 2006, The Journal of surgical research,
Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
January 2005, Basic research in cardiology,
Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
May 2014, Journal of advanced nursing,
Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
December 2012, Arteriosclerosis, thrombosis, and vascular biology,
Jin Hee Jeong, and Coral Hanevold, and Ryan A Harris, and Gaston Kapuku, and Jennifer Pollock, and David Pollock, and Gregory Harshfield
September 2011, Journal of cardiology,
Copied contents to your clipboard!